McClung, Michael R <br/><br/>
Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.  [electronic resource] 

 -  The lancet. Diabetes & endocrinology  12 2019 
 - 899-911 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2213-8595 
<br/><br/><label>Standard No.: </label>10.1016/S2213-8587(19)30346-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Biphenyl Compounds--adverse effects<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--adverse effects<br/>Double-Blind Method<br/>Female<br/>Fractures, Bone--epidemiology<br/>Hip Fractures--epidemiology<br/>Humans<br/>Osteoporosis, Postmenopausal--complications<br/>Osteoporotic Fractures--prevention & control<br/>Spinal Fractures--epidemiology<br/>Treatment Outcome